Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength (Descending) SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
33261-0745-30 33261-0745 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 31, 2007 In Use
33358-0512-30 33358-0512 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec. 2, 2014 In Use
35356-0445-30 35356-0445 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Nov. 3, 2011 Dec. 31, 2013 No Longer Used
35356-0679-10 35356-0679 ONDANSETRON HYDROCHLORIDE ONDANSETRON HYDROCHLORIDE 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 25, 2007 June 30, 2019 In Use
35356-0679-30 35356-0679 ONDANSETRON HYDROCHLORIDE ONDANSETRON HYDROCHLORIDE 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 25, 2007 June 30, 2019 In Use
42254-0097-10 42254-0097 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug. 2, 2007 In Use
42254-0212-10 42254-0212 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 27, 2007 In Use
43063-0592-04 43063-0592 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec. 26, 2017 Aug. 9, 2021 In Use
43063-0592-10 43063-0592 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec. 4, 2014 Aug. 9, 2021 In Use
50090-1015-00 50090-1015 ondansetron hydrochloride Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Nov. 28, 2014 March 31, 2019 In Use
50090-1015-01 50090-1015 ondansetron hydrochloride Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Nov. 28, 2014 March 31, 2019 In Use
50090-1015-02 50090-1015 ondansetron hydrochloride Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Nov. 28, 2014 March 31, 2019 In Use
50090-1015-03 50090-1015 ondansetron hydrochloride Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Nov. 28, 2014 March 31, 2019 In Use
50090-1015-04 50090-1015 ondansetron hydrochloride Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Nov. 28, 2014 March 31, 2019 In Use
50090-1128-00 50090-1128 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Nov. 28, 2014 In Use
50090-1128-01 50090-1128 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Nov. 28, 2014 In Use
50090-1128-02 50090-1128 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Nov. 28, 2014 In Use
33261-0761-01 33261-0761 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 27, 2007 In Use
50268-0622-11 50268-0622 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug. 5, 2016 In Use
50268-0622-15 50268-0622 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug. 5, 2016 In Use
50436-0131-01 50436-0131 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 25, 2007 In Use
51079-0525-01 51079-0525 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 9, 2007 April 30, 2019 No Longer Used
51079-0525-20 51079-0525 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 9, 2007 April 30, 2019 No Longer Used
51655-0803-27 51655-0803 ondansetron hydrochloride Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb. 23, 2015 In Use
53217-0360-01 53217-0360 ondansetron ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 18, 2018 In Use
55154-6295-00 55154-6295 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec. 5, 2012 Oct. 31, 2017 In Use
55700-0522-30 55700-0522 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral May 19, 2017 Dec. 31, 2018 No Longer Used
00378-0344-01 00378-0344 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 25, 2007 In Use
00378-0344-05 00378-0344 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 25, 2007 In Use
00378-0344-53 00378-0344 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 25, 2007 Aug. 7, 2011 In Use
00378-0344-93 00378-0344 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 25, 2007 In Use
45963-0539-30 45963-0539 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 27, 2007 In Use
67877-0170-30 67877-0170 ondansetron hydrochloride Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 25, 2007 In Use
68180-0687-55 68180-0687 Methylprednisolone Methylprednisolone 8.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral March 1, 2020 In Use
70934-0193-06 70934-0193 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb. 28, 2019 Dec. 31, 2023 No Longer Used
70934-0193-12 70934-0193 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Nov. 12, 2018 Dec. 31, 2023 No Longer Used
60687-0647-01 60687-0647 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug. 20, 2022 Aug. 31, 2024 In Use
68001-0558-55 68001-0558 Methylprednisolone Methylprednisolone 8.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Jan. 31, 2023 In Use
68084-0221-01 68084-0221 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug. 1, 2023 In Use
68084-0221-11 68084-0221 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 3, 2012 In Use
70934-0264-10 70934-0264 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral March 9, 2020 Jan. 31, 2025 In Use
70934-0264-12 70934-0264 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb. 7, 2019 Jan. 31, 2025 In Use
70518-1551-00 70518-1551 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 23, 2018 In Use
70518-1551-01 70518-1551 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral May 1, 2019 Feb. 18, 2020 In Use
70518-1551-02 70518-1551 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Nov. 21, 2023 In Use
00378-7734-05 00378-7734 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 25, 2007 Oct. 9, 2014 In Use
00378-7734-93 00378-7734 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 25, 2007 May 31, 2024 In Use
00378-7734-97 00378-7734 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 25, 2007 May 31, 2024 In Use
51655-0196-53 51655-0196 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 20, 2022 In Use
51655-0196-80 51655-0196 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 20, 2022 In Use
51655-0196-87 51655-0196 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral March 13, 2023 In Use
51655-0196-04 51655-0196 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 27, 2023 In Use
68788-9402-01 68788-9402 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 12, 2012 In Use
68788-9402-03 68788-9402 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 12, 2012 In Use
68788-9402-05 68788-9402 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 23, 2017 In Use
68788-9402-06 68788-9402 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 23, 2017 In Use
68788-9402-02 68788-9402 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 23, 2017 In Use
68788-8582-01 68788-8582 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb. 12, 2024 In Use
68788-8582-02 68788-8582 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb. 12, 2024 In Use
68788-8582-03 68788-8582 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb. 12, 2024 In Use
68788-8582-05 68788-8582 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb. 12, 2024 In Use
68788-8582-06 68788-8582 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb. 12, 2024 In Use
00069-4494-02 00069-4494 Elranatamab-bcmm Elrexfio 76.0 mg/1.9mL Immunotherapy Monoclonal Antibody BCMA, CD3 Subcutaneous Aug. 15, 2023 In Use
71288-0147-50 71288-0147 Pemetrexed disodium Pemetrexed 750.0 mg/30mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Dec. 13, 2022 In Use
63323-0621-00 63323-0621 PEMETREXED DISODIUM Pemetrexed 750.0 mg/30mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 In Use
60505-6068-00 60505-6068 Pemetrexed disodium Pemetrexed 750.0 mg/30mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 Dec. 31, 2028 In Use
68001-0545-41 68001-0545 Pemetrexed disodium Pemetrexed 750.0 mg/30mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Sept. 1, 2023 In Use
54482-0301-01 54482-0301 Pegaspargase Oncaspar 750.0 [iU]/mL Chemotherapy Miscellaneous Agent Enzyme Intramuscular, Intravenous Feb. 1, 1994 Nov. 30, 2016 No Longer Used
72694-0954-01 72694-0954 Pegaspargase Oncaspar 750.0 [iU]/mL Chemotherapy Miscellaneous Agent Enzyme Intramuscular, Intravenous Jan. 2, 2020 In Use
00944-3810-01 00944-3810 Pegaspargase Oncaspar 750.0 [iU]/mL Chemotherapy Miscellaneous Agent Enzyme Intramuscular, Intravenous Feb. 1, 1994 May 16, 2020 No Longer Used
72694-0515-01 72694-0515 Calaspargase Pegol Asparlas 750.0 U/mL Chemotherapy Miscellaneous Agent Enzyme Intravenous Sept. 27, 2019 In Use
76128-0155-75 76128-0155 Porfimer sodium Photofrin 75.0 mg/31.8mL Chemotherapy Photosensitizing Agent Cytotoxin Intravenous Dec. 27, 1995 In Use
00187-5526-75 00187-5526 Bexarotene Targretin 75.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Dec. 29, 1999 In Use
00378-6955-01 00378-6955 Bexarotene Bexarotene 75.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral July 9, 2015 In Use
68682-0003-10 68682-0003 Bexarotene Bexarotene 75.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Dec. 17, 2015 In Use
00069-0187-21 00069-0187 Palbociclib Ibrance 75.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral Feb. 3, 2015 In Use
00054-0399-25 00054-0399 Bexarotene Bexarotene 75.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Nov. 11, 2020 In Use
70255-0025-01 70255-0025 Encorafenib BRAFTOVI 75.0 mg/1 Chemotherapy BRAF Inhibitor V600E Oral June 27, 2018 In Use
70255-0025-03 70255-0025 Encorafenib BRAFTOVI 75.0 mg/1 Chemotherapy BRAF Inhibitor V600E Oral June 27, 2018 In Use
70255-0025-05 70255-0025 Encorafenib BRAFTOVI 75.0 mg/1 Chemotherapy BRAF Inhibitor V600E Oral Aug. 3, 2020 In Use
70255-0025-06 70255-0025 Encorafenib BRAFTOVI 75.0 mg/1 Chemotherapy BRAF Inhibitor V600E Oral Aug. 3, 2020 In Use
00832-0285-00 00832-0285 Bexarotene Bexarotene 75.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral July 25, 2018 In Use
69238-1250-01 69238-1250 Bexarotene Bexarotene 75.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Sept. 4, 2018 In Use
59572-0775-01 59572-0775 Luspatercept Reblozyl 75.0 mg/1 Immunotherapy Erythropoiesis-Stimulating Agent Subcutaneous Nov. 8, 2019 In Use
00069-0284-03 00069-0284 Palbociclib Ibrance 75.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral March 30, 2020 In Use
00078-0681-66 00078-0681 Dabrafenib Tafinlar 75.0 mg/1 Chemotherapy Enzyme Inhibitor BRAF Oral April 1, 2016 In Use
43975-0315-10 43975-0315 Bexarotene Bexarotene 75.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral May 10, 2018 In Use
00591-2832-01 00591-2832 Bexarotene Bexarotene 75.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Nov. 11, 2021 In Use
49663-0002-25 49663-0002 Cysteamine bitartrate PROCYSBI 75.0 mg/1 Chemotherapy Cystine-Depleting Agent Oral April 30, 2013 Feb. 28, 2019 No Longer Used
00173-0847-08 00173-0847 Dabrafenib Tafinlar 75.0 mg/1 Chemotherapy Enzyme Inhibitor BRAF Oral June 10, 2013 May 31, 2018 No Longer Used
00173-0847-61 00173-0847 Dabrafenib Tafinlar 75.0 mg/1 Chemotherapy Enzyme Inhibitor BRAF Oral June 10, 2013 Dec. 11, 2014 No Longer Used
00173-0847-65 00173-0847 Dabrafenib Tafinlar 75.0 mg/1 Chemotherapy Enzyme Inhibitor BRAF Oral Oct. 8, 2014 May 31, 2018 No Longer Used
62856-0602-10 62856-0602 Bexarotene Targretin 75.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Dec. 29, 1999 Dec. 1, 2014 No Longer Used
75987-0140-13 75987-0140 Cysteamine bitartrate PROCYSBI 75.0 mg/1 Chemotherapy Cystine-Depleting Agent Oral Feb. 14, 2020 In Use
75987-0140-14 75987-0140 Cysteamine bitartrate PROCYSBI 75.0 mg/1 Chemotherapy Cystine-Depleting Agent Oral Feb. 14, 2020 In Use
63539-0284-03 63539-0284 palbociclib Ibrance 75.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral March 30, 2020 In Use
42291-0072-01 42291-0072 Bexarotene Bexarotene 75.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral April 14, 2023 In Use
42292-0007-01 42292-0007 Bexarotene Bexarotene 75.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral April 15, 2016 Jan. 31, 2020 No Longer Used
42292-0007-10 42292-0007 Bexarotene Bexarotene 75.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral April 15, 2016 Jan. 31, 2020 No Longer Used
72730-0202-01 72730-0202 infigratinib TRUSELTIQ 75.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR Oral May 28, 2021 In Use

Found 10,000 results in 6 milliseconds — Export these results